Connect with us

Hi, what are you looking for?

High Times


FDA Panel: Not Enough Data to OK ‘Abuse-Deterrent’ Opioid

Photo by frankieleon via Flickr


TRENTON, N.J. (AP) — A panel of Food and Drug Administration advisers voted against approving a new opioid painkiller with a unique feature for deterring abuse: It releases a deep-blue dye if someone tries to get high by crushing, chewing or snorting pills.

Panelists voted overwhelmingly against approving Intellipharmaceutics International’s generic version of extended-release Oxycontin, a key drug in the U.S. opioid addiction epidemic. The FDA usually follows its advisers’ advice.

Doctors and scientists raised many concerns about the dye’s safety for intended patients, and its effectiveness in deterring opioid abusers. Most said the company hadn’t done enough studies of the drug.

Some suggested blue stains around the mouth or nose from trying to abuse the drug could become popular among addicts. Others said the dye’s “Scarlet Letter” shaming approach was insensitive.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


HT Newsletter

Subscribe for exclusive access to deals, free giveaways and more!

Thank you for subscribing.

Something went wrong.


You May Also Like


The theory that cannabis can help reduce opioid dependency is getting more support.


as regulaciones federales limitan el alcance que podría tener probar con marihuana en pacientes, a diferencia de los rigurosos estándares de prueba para otros...


The site will be the first of its kind in the nation.


The plan will also address racial disparities in opioid-related deaths.


The real high level drug dealers are finally being held accountable.


The program will prioritize support for those seeking treatment.


New spending package initiates key changes to tobacco laws.


The surveillance systems track overdoses in real time.

Do NOT follow this link or you will be banned from the site!